HUE033352T2 - Biciklusos vegyületek mint alfa4-béta2 nikotinos acetilkolin receptor ligandumok - Google Patents

Biciklusos vegyületek mint alfa4-béta2 nikotinos acetilkolin receptor ligandumok Download PDF

Info

Publication number
HUE033352T2
HUE033352T2 HUE09818648A HUE09818648A HUE033352T2 HU E033352 T2 HUE033352 T2 HU E033352T2 HU E09818648 A HUE09818648 A HU E09818648A HU E09818648 A HUE09818648 A HU E09818648A HU E033352 T2 HUE033352 T2 HU E033352T2
Authority
HU
Hungary
Prior art keywords
azabicyclo
esia
compound
yloxymethyl
hexane
Prior art date
Application number
HUE09818648A
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Abdul Rasheed Mohammed
Srinivas Veeramalla
Srinivasa Rao Ravella
Ishtiyaque Ahmad
Pradeep Jayarajan
Anil Karbhari Shinde
Rama Sastri Kambhampti
Gopinadh Bhyrapuneni
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of HUE033352T2 publication Critical patent/HUE033352T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (4)

  1. «««OS VEGYÜLETEK: M!NT ALF&4-BÉTA2 NIKOT1NOS ACETIí AiOLm RECEPTOR 1 MiANDEMOS : :lgÉí|:piOfe; 1 Y&gvkuík t kbw'ík«V{> >Γ> aPalaaoN aopious
    U* és aznk $ztereobo«K*rki vagv jjyógyá^zaiHag eltogadható soi; aiHíi R {dentóse anKxopofí vagv heseraan; esopork R, K'SewoM' hub''-cí.‘uauw^ dUk<\op'>5s vae> >aU\xdksK'M>pao'; R c i'R’^c hidu>^0-»xju>sa, aíku csopa<k dW\* ιν'^Ά, 0íU<»<<!kil-^.."'iOíi< aíke>ukd aikd'cxoport, oVU>alkw¡>eso|jort. smi-csopork keíeKKíUd- ci^per? vagy heiemdkUkaíksl-esopfHl; R\ jdentése iddrogénatom. hsdroxi-eaopori, haiogénatum* ko-&amp;soports naro~caopott, íunsd-csopori, amm-esoporp karboxii-csoport, dkii-eva¡*.ak a*K'*v vp'pon, eAuíalkd-c.soporr. esk)uafkd"»skü--esopork cikkwikoxi-csopoít, kdogeswükd es* sport, hanger-a->d->s\< o?opo5k heu ^i-vskiü csopusi \ag\ ίκΚ'ίοοΑΗ-ΰΐΜί-ονίρ^ίΐ, >jn" artóke 1 -tos 4-sg seneo; ,as" erléks,' i -tól Asg foned »p" atéke 0-t<d 2-ig sened, a/,?ai a idfétdlek hogy a w^úíwmmm a UnctMVo p'd kcpioiu νι^'Ή'1 ^ PtVí:
    (A). Jk Aggfklet a® h igtnypotH s¿ennk amdy a küveíke/ikltes 41 k> esoporíbof v.kp váii§?|.Vá< d-(pifHjin'd'd' ox i-meb i }-2-azabtcíklo|3.1.Ofhexáo-d* akssx>&amp; iond; 2-ítjetn->-{piridínAvH-,».KMi«íiil>-:-ii?abicikIof3.i.01ht*xáíi; 3··; a ·medbpuidkK'-P;· j~oxs -nuríd í-^axabicikiot 4-1 .Ofiiexáñ-dshídrokloríd; * L abn puídrs-' iPoxí n taP-J cvabk'ikM * 1 u;!v\dn'dih«1sv>kk>n*k * < ' Hoi-psnd e~* i nv' ¡s\al ' abk skk>[' $ Odk\ bh'dsok asa 4 A ü' os aukísa " t* om s'kt s C a\*Hu\ oA ' t',i N dsbkluAl > ^«SAk'í-p»tdií>>^-íi oxs-mc'dlid^akioskksfdJ.OdH'xan dshdrokk'fui, 1 ν' bíoíS-i p»»»o ' í \ <-v > \ í'p ? (e^alik\' 1 Ήϊννη» ^uar u ks3 ticos psssxbn- * U ''AwnHúi·N '>Uoj3 kihex sst km swk 3' bMluot · ptrsdts*· 3-i \ - o\o sne-tü p 2xaetUO» axabññUo|3.1,0}ist-NaO'ta*Mál:k * ! 3'kÍ0S'pslíCÜn < d ' \ ΊΠίΗί.Π-,'' sectil-2 x/ab'C*kkv ' i ^ííIvá sn; 2- ss)eük3-(2-msddpiskbsn3-skoxks$seidk2';sxabse8kM 3. i .OlhexáiK 2 - metil '3'{2-81)0851- psndtn-S di-oas -ose? íi s^mxabicskiol ?. i .OJhcssák ^ K O* Wli"i N i \ ss.'U 4 2 ¿i ' do ^ ' <t \n »' 3- t2-t1uor-pm8Hi)“5”ií'Oxkinefii)'-2-metií-2-a?.abicikkíf3i.L0}hexin: 3-(S-kibo psmtin-.il· skoxkroesif}' 2 msebk2--m:abicski<H3· í ,.0]hexásv. i f-»rom psnsho y-d-orn-oscnl)-4 mcul 3 xSxOíkK'sU 33 \ t s j h e χ a o ~4 s o ¡ d ío t- 1 os¡o' 3·-«2·ΓηοΡΐφίήί!ίϊ5·'3'8ΐ-οχ!-{·{ϊούΓ;<2'·3ΧδΙ'>ϊθϊΚ1ο|}.1<0!Ι'8οχ;ΐ!ρ 5-(2'a«?»biojklof3.LO|hex-3'iI-TOetoxi^n<li«-'2*karb<msavv3í?ud<· ."Wií-a'abioUo!* i k>lhc\ 3 sl-me-orn spsndm 3 kasívtsM\, ' v-ksíset^M'pisfdso 3 ú í'\-5no'u;-3-χ/λ!'<;cikk¡I3 i Olbevan; 3-{2-i-<í:opvo|X>\i-pmcíin--3-i!*nxi-n)eíil)>2-3£ab5dk!«|3.LO|hexán; s «3'íivnl 3 ^'sk^vilhílJ.kdlbex < d-sootoM'>p>s*Ji*s*2 k^bor·^ mnsd 5-{2-m#íll'*t-#í&amp;bjdklo(3.l.0)hesK^bmetoxí)pindin-'2-ka?bonp-y-; ks 2'sooun kpsm.ksv5--Ü -ox s-rnedi Komiedl '2~a/ahsdkioj 3,1.0 jhexatr. 3"(2“Szopfopoxi'pkid5n--5^i!-Px{--n5e5Uk2-íi)eUl-2-axafeieikto(3>LÍÍ:]b3xÉk 5*f I -(2axabíelkíop. 1.0)hex>3-ii}-eíoxi|piñ<ün--.2--il·-aisímÍ 3-i2'psm>ikbss 1 -si-p?rsd< n -5- d - ox s~ ose? si k3-a/a-bie;ki o| 3.1 k|hcxs*ss; ρ {* i.2 mcfsi 2 oxd\cíMo|,4 I Ο^ν mKtoxs psudsss 2 n xtmitn 2- mv f s k3 4 2 - putos sdin- i -i k ps ddi ss- 5- i 1 -ox s- ¡neis k 2 svx &amp; b ic i b !op. ΙόφΜ&amp;η í .>( pirsdsss- 3- si -oxs-mdsi í-2-;wabidkksj4,1 Jkhepkd:. 3np snetb psndm 3-d-oM'STíosdo2-tl/aHuüojd 5 0}?u ptám M2«meHi-pmdin-3-if-oxkmeíi!V2-a*abfcík)0Í4JxO]hepuln: o ' do psísd'ii * ss ή m« ^ ' u/absesv x»{ - 1 k >< pnt' ¿-medí-3-(2 · metH~pir}diO'3»ü*fjíxkmob1)'2-aü;ahiclkio( 4. i .0 lheprá«| ki5-ki3s-psrkisn-3-si-oxs-míHÍIk2-sne?ík2'íw.sibk'skkvi4J.0]|Hpkm; P'i» SI * (<\!\V¡ "* ^ drtx*k<‘{ M k||'í,s<iJ 442-(5-21or- pirix i i ¡v- 3 -d - o x i )e til k 2- ssies i! - 2 - ax a hk i kioi 3 4.0 i he a ass; 3 (piridi η-3-ií - οχ i-stveii 0-2 -axabicskloH I .Olísepfxln-h kirok lorsd: 3- {5-klór-piíkilo-3-d-oxs-meiily^-axabitsklo|4. i Adhepsnn--hidt<>ktofid; .<&amp;: íixok v/so!T<;m>merj£Í vagy gyógváHxatüssg eifogadható aói. 3» Vegyñíet a* I. igéssyponi vxetifiL ¿ssiiesy egy s/erveU«« sawa* x agy pgy sxervo 'sav'val alkoloH gydgyászuiüag ellUgadfvatd savaddíaés so h.smssijában ál! roíidoíkoxxksrc* alio! « n a'Dodosi \<s\ xS kxíxcfkc/O' bsPsnh'xdfoyiesoxsx ds^ds^hubnvo k koí'^.si, xaMsosiOxj^ vagy k-i\;dos'sav; é;> ;s ΧίΧΟχχχ *av si kdveíkexo: bosostyásikdsav, nsaieifsxa^ t mnsav, fsiixíxüx»' cliso i>á\ xísmxOxS'v %>tkoxxSX' bt>i/t»cvu. r ^i„siívc p-soiuoN «ik'nxas sooiJsixX£i¡ybosav vagy ¡'SüiVaiónsic.idfoíssav'.
  2. 4. EijAráx egy u?. \. sgdnypom sxe.dnsi i!) ákakioos kcpleiü vcgyükissek xx esoáHHasáoí: kjvéxe. hugy a? (3i) kcpíesü vcgyiliet blnil Isxás'vk; imÉy fijarás- migában Asgiaija k kovcrkeiíókes' (a) a Ipvpkead (í) llfslinos Mplsiü ¿ttgállM&amp;P -a. MaáRtP$ (9) iltállnós Id ρ fe? a tlMf (dib v egydlstM;
    í $ l haga egy a Mvaikesp
    ib) a Π.0) ált&amp;Maox fcéaléib eegyakt átalaféMsa a Mxefkesft d i ) ákafános kéglerü íMp vadeas: aegybfcaé lámele eegyüies. eéd&amp;sog&amp;ríjaaak as ellávelífása aMesa);
    le) a {1/1): Ikaláeoa képfeíü vegyLUes lakaMiása as t!) ékaiánox kbplesü vagyüleué, opemaál&amp;áa ar(I> ibalasies kgpMü vegyllM ltafakáá% annak egy gyégyásyunüag diegadheP djuvá: aba! Id Ru Rj:, 1¾¾ es n es p jeleádse as 1, Igdaypontbaa aieghadrosdsak sserielk 5> /Bljérls egy as .), Igsaypaef asedad (I) ál.íaláam képMd vegyülepek as elMBfiadíá, :kivdm hogy ás iá.) kepis!)! vsgyulgt apea klsásda, abo! as a ikpvetkeso fi!) átedloes képkaü;
    (Í|.): : ame I v t-lJMl m&amp;gáfeaa 1¾¾¾¾ a teVeitefttól (a) g kdvetkead: (8) akMáMá fcif%tlky«fyf!#f rfgglltaíása ¡a klveito# (9.) tialldos képküi h i tiras: i í -vegyü leliéb
    «9) bagy ágg a kPvaiMyiC10| ágsjánaa képhnü vegyyfeí legygablpyyvg:
    :(b> a (ib) áltaianos kepíefM vegyükf: átatókitósa a [i,í¡ állaláaes képialu Pesia y#tet vsgykiettk (amsly yygyüfetvádbesopofijáñálv ay eMveiMsy tb?t|ál); alio! Ib Rs, 11¾ Es, m, a és p jglgpífee az lyIggnyponflMígffiaglíaMraáOíbE saebabo E E||ás'ás ay 5, igsswpopi sze#«g aboba: (10} gkalános klpMb vegyuioi a (i i:) al^aaos Mpfera vsgytbeOg sfeíVpyk vágy piñuorkavMk (ibfíacsr'-éaataavaalc) egy oldosxorbes? Idodoo áika(p):aylaáya| van iMfakftxk pildáol ogy oMésaorke», ameiy a kgv&amp;ikMgk kdyül van válasviva: eíamik MmfekímfUé&amp;í, joluo!, gbkaodíág lyópyjpaaük dtyOlkkk dlkidyynefga vagy azdk egy kgvarlke; ", amdx '„a'Jdxa< egx , , igc«xpen* */νηιαι \C£\ukk% km-xa Ιη>λ aa Λ11' epK'ii xegx.dot as».' xagx cí\' χ- sgfm\p*«u\,»p , ' s¿y»A'om $mte i ί vegyttl etet * kNogxa^ab kí-íítnu:^ a " «ρόχροΉΐ .v*eHnt, jiaI) x.***ahj*.x.» ^ - vs h'H* ku>' «o o<t'U lagonsfi .¾ vO'-cAe^k^o! ,iH" O'-opouM M-as/^a ^ U! κμ'ΡΚικΑ, ι<-\ΒΛ moerz agomstók é\ más aikotmos aceühmím recepirnok,
  3. 9. Gyógyác/au kéteínaér>y a 1. igátypont vagy a 8. igénypoitf szmnt. ameíy a kx>ve*ke?,6fc tn xvSÜeiU'VSKí. oa> hiNoua, karvA. por. vopoga»' taH^uk s " ' « ^ * j ' \ *"\ n *ep obi a «* io >», > χ'ίν ΐ! " iNs», a*vl „ ws , } .j '! iU» iN sj?> >.' do \ a' > yKv^v^v'ívW'n tóríéñci amigo lito, Ni (oogyus^ati kc$/iwjtn> -s Ά-ίδϊ <Mg igénypomok bárnwiyike szenni, eg> aUapctnek a ko<rclvν'Κ'χχ 'oitooo aikAnoso>\ra, amo)' a koxmke'<A kcvui xa» xala.Níí’x.i. hopo egv koamov roemoria?.»x.«· saagolur , lOgníoyf' mcmory assisisiei"). iujdaiom· vagv eihtek. il Vegyiskf :« L igé»ypmd sztnm, kiveve, hogy az sA> kdpleíü vegyükt «mes kizárva, xag> vxygusk't á 2 igoaxpos« xaya a " oaiopom \,>er,m gYoyAtN¿..»'i uaxoso ¿dkalomAVaa. Í2> Vcgyükn az L igénypont seriar, kivtvc. hogy a?. (A) kdpieiü vegydlei nirics Kizárva. vagy vegyüks a 2. igénypont vagy a 3. igdnvpom sraiti, beieg&amp;égeknek a kttrd&amp;fteR ibmioD aikalmazáani, amdyek «40? »ik toninos recepíorral kapesolaíoyak.
  4. 13, VegyUlet a¿ 1, igénypom sxeribftt, fcivévc, hogy a* (A) képlerü vcgytHel nines kixám. vgv >cgu¡Ut a 2 igsnvpom xa«x ai igenxpom ko/uí Kirmdvsk vennt, cg\ aHapotnak a k> sVi' ·>χ*Κ*« ν«Α\ν> ..akal»»» >ook amch i kuXYí^<ik \oaOi xa» vaí«»-ftxa 'kp^^vao ogy kogníuv mesoón;o'.avia' ómgohik «cognúive memory xlssoidor*'), íáglalooi vagy esmziv
HUE09818648A 2009-11-18 2009-12-31 Biciklusos vegyületek mint alfa4-béta2 nikotinos acetilkolin receptor ligandumok HUE033352T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2838CH2009 2009-11-18

Publications (1)

Publication Number Publication Date
HUE033352T2 true HUE033352T2 (hu) 2017-11-28

Family

ID=42228992

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09818648A HUE033352T2 (hu) 2009-11-18 2009-12-31 Biciklusos vegyületek mint alfa4-béta2 nikotinos acetilkolin receptor ligandumok

Country Status (24)

Country Link
US (1) US8735423B2 (hu)
EP (1) EP2513085B1 (hu)
JP (1) JP5536227B2 (hu)
KR (1) KR101376145B1 (hu)
CN (1) CN102741239B (hu)
CA (1) CA2773409C (hu)
CY (1) CY1118361T1 (hu)
DK (1) DK2513085T3 (hu)
EA (1) EA020506B1 (hu)
ES (1) ES2601905T3 (hu)
HK (1) HK1175782A1 (hu)
HR (1) HRP20161461T1 (hu)
HU (1) HUE033352T2 (hu)
IL (1) IL219637A (hu)
LT (1) LT2513085T (hu)
MX (1) MX2012005637A (hu)
NZ (1) NZ600536A (hu)
PL (1) PL2513085T3 (hu)
PT (1) PT2513085T (hu)
RS (1) RS55469B1 (hu)
SI (1) SI2513085T1 (hu)
SM (1) SMT201600444B (hu)
WO (1) WO2011061751A1 (hu)
ZA (1) ZA201203522B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296710B2 (en) * 2011-06-17 2016-03-29 Eli Lilly And Company Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist
JP6103240B2 (ja) 2013-11-18 2017-03-29 トヨタ紡織株式会社 ピッチ材料の調整方法及び調整装置
US10945771B2 (en) 2017-06-09 2021-03-16 Merck Sharp & Dohme Corp. Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2023135528A1 (en) 2022-01-11 2023-07-20 Suven Life Sciences Limited Heteroalicyclic derivatives and their use in the treatment of cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
AU7871498A (en) * 1996-12-20 1998-07-17 Novo Nordisk A/S A method of treating hypercholesterolemia and related disorders
IL146288A0 (en) * 1999-06-30 2002-07-25 Daiichi Seiyaku Co Vla-4 inhibitor compounds
US20040192673A1 (en) 2001-05-05 2004-09-30 Pascale Gaillard N-aroyl cyclic amine derivatives as orexin receptor antagonists
FR2889187B1 (fr) 2005-07-28 2007-09-07 Servier Lab Nouveaux composes 1,1-pyridinyloxycyclopropanamines polysusbstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
EP2513085A1 (en) 2012-10-24
US20130072518A1 (en) 2013-03-21
EP2513085B1 (en) 2016-09-28
ZA201203522B (en) 2013-01-31
EA201290344A1 (ru) 2012-10-30
MX2012005637A (es) 2012-06-13
HRP20161461T1 (hr) 2017-01-27
DK2513085T3 (en) 2016-12-05
RS55469B1 (sr) 2017-04-28
AU2009355487A8 (en) 2012-07-12
CA2773409C (en) 2015-06-16
CN102741239A (zh) 2012-10-17
ES2601905T3 (es) 2017-02-16
NZ600536A (en) 2013-05-31
US8735423B2 (en) 2014-05-27
LT2513085T (lt) 2016-12-27
CA2773409A1 (en) 2011-05-26
JP5536227B2 (ja) 2014-07-02
PL2513085T3 (pl) 2017-09-29
SI2513085T1 (sl) 2017-02-28
EA020506B1 (ru) 2014-11-28
AU2009355487A1 (en) 2012-05-31
CY1118361T1 (el) 2017-06-28
WO2011061751A1 (en) 2011-05-26
SMT201600444B (it) 2017-01-10
IL219637A (en) 2015-10-29
KR101376145B1 (ko) 2014-03-19
AU2009355487B2 (en) 2013-10-10
KR20120049943A (ko) 2012-05-17
JP2013510901A (ja) 2013-03-28
HK1175782A1 (en) 2013-07-12
PT2513085T (pt) 2016-11-14
IL219637A0 (en) 2012-07-31
CN102741239B (zh) 2015-06-24

Similar Documents

Publication Publication Date Title
AU2010337837B2 (en) Alpha4beta2 neuronal nicotinic acetylcholine receptor ligands
DK2507225T3 (en) L-DIHYDRO-2-OXOQUINOLIN COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS
HUE033352T2 (hu) Biciklusos vegyületek mint alfa4-béta2 nikotinos acetilkolin receptor ligandumok
US11278530B2 (en) Polycyclic amides as muscarinic M1 receptor positive allosteric modulators
AU2009355487C1 (en) Bicyclic compounds as alpha4beta2 nicotinic acetylcholine receptor ligands